# Cabergoline-Resistant Recurrent Macroprolactinoma During Pregnancy: A Case Report and Review of the Literature

## TL;DR

A woman with a rare cabergoline-resistant macroprolactinoma faced tumor recurrence during pregnancy, requiring urgent surgery and multidisciplinary care to ensure a healthy outcome.

## Contribution

This case highlights the challenges of managing dopamine agonist-resistant macroprolactinomas during pregnancy.

## Key findings

- The patient experienced tumor recurrence within three months of stopping cabergoline.
- Multidisciplinary care was essential for managing the tumor and ensuring a healthy pregnancy outcome.
- Cabergoline resistance persisted despite high-dose therapy and tumor recurrence during pregnancy.

## Abstract

We report a rare case of cabergoline-resistant recurrent macroprolactinoma during pregnancy. A 34-year-old woman, 17 weeks pregnant, presented with a four-week history of headache and a one-day history of visual disturbance. The medical history was significant for a macroprolactinoma with pituitary apoplexy, which was treated with an emergent pituitary resection approximately two years and four months before this presentation. At that time, postoperative prolactin levels improved but remained elevated despite gradually escalating cabergoline doses up to 6 mg per week. Our patient met the established criteria for cabergoline resistance, with persistently elevated prolactin levels despite high-dose cabergoline therapy. She was dealing with resistant hyperprolactinemia, causing infertility. The patient decided to conceive, and pre-pregnancy counseling was done by reproductive endocrinology, maternal-fetal medicine, and a genetic counselor. Before conception, magnetic resonance imaging (MRI) of the pituitary showed postoperative changes from transsphenoidal hypophysectomy and expanded partial sella, with no clear tumor, and the prolactin level was 228 ng/mL (non-pregnant normal reference range: 3-30 ng/mL). She had in vitro fertilization done, and cabergoline was discontinued on confirmation of pregnancy. On presentation, MRI of the pituitary revealed a recurrent pituitary macroadenoma (29 × 29 × 27 mm). She developed symptomatic tumor recurrence within three months of stopping cabergoline, and her prolactin level was 1,669.8 ng/mL (normal reference range in pregnancy: 10-209 ng/mL). She was treated with steroids, and cabergoline was restarted. However, the tumor continued to grow, causing symptoms necessitating repeat urgent pituitary resection in the second trimester of pregnancy. She remained on cabergoline through the rest of her pregnancy and delivered a healthy male neonate via cesarean section, done for breech presentation at 39 weeks. The postpartum, fetal, and neonatal stages were all uneventful. This case highlights the complexities of managing dopamine agonist-resistant macroprolactinomas during pregnancy and underscores the importance of individualized, multidisciplinary decision-making to optimize maternal and fetal outcomes.